reports
Build-A-Bear Workshop to Announce Third Quarter Fiscal 2024 Results an...
ST. LOUIS--(BUSINESS WIRE)-- Build-A-Bear Workshop, Inc. (NYSE: BBW) today announced that the Company will report third quarter fiscal 2024 results for the period ended November 2, 2024, on Thursday, December 5, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host its quarterly investor conference call to discuss the results at 9 a.m. ET on the same day. The dial-in number for the live conference call is (201) 493-6780 (toll/international) or (877) 407-3982 (toll free). The access code is Build-A-Bear. The live Internet broadcast may be accessed at the ...
Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare ...
Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference GARDEN CITY, N.Y., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of Nitric Oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in one-on-one meetings and a fireside chat at the Piper Sandler 36th Annual Healthcare Conference being held December 3-5, 2024 in New York. Fi...
Build-A-Bear Workshop, Inc. Declares Quarterly Cash Dividend
ST. LOUIS--(BUSINESS WIRE)-- Build-A-Bear Workshop, Inc. (NYSE: BBW) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on the issued and outstanding common stock of the company. The dividend will be paid on January 9, 2025, to all stockholders of record as of November 27, 2024. About Build-A-Bear Since its beginning in 1997, Build-A-Bear has evolved to become a beloved multi-generational brand focused on its mission to “add a little more heart to life” where guests of all ages make their own “furry friends” in celebration and commemoration of l...
Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and P...
Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 17% compared to the previous quarter ended June 30, 2024 Strengthened balance sheet is expected to provide sufficient cash runway through June 2026 Completed a $20.6 million private placement offering with multiple healthcare-focused institutional funds and Company insiders Retired $17.5 million in debt from Avenue Capital and entered into a $11.5 million loan agreement with an insider-led investor group Conference call scheduled for 4:30 p.m. ET today, November 11t...
Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-...
Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting - LV UNO in combination with anti-rPD-L1 resulted in prolonged survival and doubled the tumor growth inhibition rate in MAT B III tumor bearing rats compared to anti-rPD-L1 alone - LV UNO compares favorably to HV UNO administration in reducing tumor volumes in combination with anti-mPD-1 in CT26 BALB/c mice - Increased nitro-tyrosine staining in LV UNO treated tumors indicates an improved dis...
- Wedbush Research
LOGI LOGITECH INTERNATIONAL S.A.
XNCR XENCOR INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TRIP TRIPADVISOR INC.
NRZ NEW RESIDENTIAL INVESTMENT CORP.
NHI NATIONAL HEALTH INVESTORS INC.
MFA MFA FINANCIAL INC.
MELI MERCADOLIBRE INC.
GPC GENUINE PARTS COMPANY
DIN DINE BRANDS GLOBAL INC.
CXW CORECIVIC INC.
AZO AUTOZONE INC.
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
AAP ADVANCE AUTO PARTS INC.
ORLY O'REILLY AUTOMOTIVE INC.
ZG ZILLOW GROUP INC. CLASS A
DNLI DENALI THERAPEUTICS INC
LYFT LYFT
RVMD REVOLUTION MEDICINES
CRSR CORSAIR GAMING
KROS KEROS THERAPEUTICS
GBIO GENERATION BIO
NUVB NUVATION BIO INC (A)
ELEV ELEVATION ONCOLOGY
GHLD GUILD HOLDINGS
TNGX TANGO THERAPEUTICS
APP INC
BROS APPLOVIN CORP
DUTCH BROS INC
- Ritika Das
- Robert Driscoll
- Sam Ravina
Revolution Medicines Reports Third Quarter 2024 Financial Results and ...
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging safety, tolerability and antitumor activity in patients with PDAC harboring a KRAS G12D mutation Company on track to provide update on lung cancer programs in the fourth quarter of 2024 Revolution Medicines to hold webcast today at 4:30 ...
Revolution Medicines to Participate in Upcoming Investor Conferences
Revolution Medicines to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at Guggenheim's Inaugural Healthcare Innovation Conference and the UBS Global Healthcare Conference. Details of the company’s participation are as follows: Guggenheim's Inaugural Healthcare Innovation Co...
Revolution Medicines to Report Financial Results for Third Quarter 202...
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024 REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 6, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), members of Revolution Medicines’ senior management team will host a webcast to discuss ...
Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Con...
Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the second quarter of its fiscal year 2025 ended September 30, 2024 on Monday, November 11, 2024 after the market closes. Conference Call & ...
- Ritika Das
- Robert Driscoll
- Sam Ravina
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy S...
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging tolerability and antitumor activity in patients with PDAC Investor webcast to be held Friday, October 25 at 12:00 p.m. Eastern Time (ET) REDWOOD CITY, Calif., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced preliminary safety a...
- Ritika Das
- Robert Driscoll
- Sam Ravina
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy S...
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma Encouraging progression-free survival and overall survival profile Safety findings consistent with previously reported data, no new safety signals observed Investor webcast to be held Friday, October 25 at 12:00 p.m. Eastern Time (ET) REDWOOD CITY, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced encouraging antitu...
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Ev...
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the first patient has been dosed in RASolute 302, a Phase 3 registrational study of RMC-6236, a RAS(ON) multi-selective inhibitor, in patients with previously treated, metastatic pancreatic ductal adenoc...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
MOFG MIDWESTONE FINANCIAL GROUP
MITK MITEK SYSTEMS INC.
MEI METHODE ELECTRONICS INC.
KVHI KVH INDUSTRIES INC.
HNRG HALLADOR ENERGY CO.
I3N CHART INDUSTRIES INC.
GDOT GREEN DOT CORPORATION CLASS A
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
CDXS CODEXIS
ANGO ANGIODYNAMICS INC.
AHH ARMADA HOFFLER PROPERTIES INC.
NEWT NEWTEK BUSINESS SERVICES INC.
A0JMXQ INDIA CAPITAL GROWTH FUND LTD.
HTLD HEARTLAND EXPRESS INC.
ORN ORION GROUP HOLDINGS
EBF ENNIS
GATX GATX CORP
APTV APTIV PLC
CLAR CLARUS CORPORATION
RFIL RF INDUSTRIES LTD.
NANX NANOPHASE TECHNOLOGIES CORP.
AXR AMREP
ETON ETON PHARMACEUTICALS
STIM STIMSONITE CORP
INMB INMUNE BIO
NFE INC.
GCI NEW FORTRESS ENERGY
CAPR GANNETT CO. INC.
FBIO CAPRICOR THERAPEUTICS
VRDN FABIEN CORP
NUVB VIRIDIAN THERAPEUTICS INC
CTLP NUVATION BIO INC (A)
SMMT CANTALOUPE
PFBX INC.
BMEA SUMMIT THERAPEUTICS INC
PCT PEOPLES FINANCIAL CORP. (MISSISSIPPI)
BHVN BIOMEA FUSION
BIGZ INC.
BUKS PURECYCLE TECHNOLOGIES INC
VEEE BIOHAVEN LTD
CDIO BLACKROCK INNOVATION AND GROWTH TST
SRFM BUTLER NATIONAL CORP
CRBP TWIN VEE POWERCATS CO
BTSG CARDIO DIAGNOSTICS HLDGS INC
ASGI SURF AIR MOBILITY INC.
OCX CORBUS PHARMACEUTICALS HOLDINGS INC.
PMN BRIGHTSPRING HEALTH SERVICES INC.
BNTC ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
CLNN ONCOCYTE CORPORATION
BNZI PROMIS NEUROSCIENCES INC.
SIRI BENITEC BIOPHARMA INC
CLENE INC
BANZAI INTERNATIONAL INC
SIRIUS XM HLDGS INC NEW
- David Nierengarten
- Dennis Pak
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
- Wedbush Research
DPZ DOMINO'S PIZZA INC.
KMX CARMAX INC.
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
XNCR XENCOR INC.
WDC WESTERN DIGITAL CORPORATION
WAL WESTERN ALLIANCE BANCORP
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RWT REDWOOD TRUST INC.
PEGA PEGASYSTEMS INC.
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NRZ NEW RESIDENTIAL INVESTMENT CORP.
MFA MFA FINANCIAL INC.
KURA KURA ONCOLOGY INC.
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FTNT FORTINET INC.
CYBR CYBERARK SOFTWARE LTD.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
CAKE CHEESECAKE FACTORY INCORPORATED
ABR ARBOR REALTY TRUST INC.
WD WALKER & DUNLOP INC.
CMA COMERICA INCORPORATED
CVNA CARVANA CO. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
RCUS ARCUS BIOSCIENCES
ZS ZSCALER INC.
RC READY CAPITAL CORPORATION
COOP MR. COOPER GROUP INC.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PFSI PENNYMAC FINANCIAL SERVICES INC.
RVMD REVOLUTION MEDICINES
ORIC ORIC PHARMACEUTICALS
RKT ROCKET COMPANIES
IMNM IMMUNOME
WOOF PETCO HEALTH AND WELLNESS
DAWN DAY ONE BIOPHARMACEUTICALS INC
GHLD GUILD HOLDINGS
TNGX TANGO THERAPEUTICS
UWMC INC
TYRA UWM HLDGS CORP
EWTX TYRA BIOSCIENCES INC
RBRK EDGEWISE THERAPEUTICS INC
RUBRIK INC
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.